文献速递外周动脉疾病

共病多重用药评分与慢性肢体威胁性缺血炎症标志物的关联

Linking Comorbidity and Inflammation: The Role of Comorbidity Polypharmacy Score in Chronic Limb-Threatening Ischemia.
PubMed 文献 · Ann Vasc Surg · 2025-06-17

该回顾性研究纳入442例在锡耶纳大学血管外科接受择期血运重建的慢性肢体威胁性缺血(CLTI)患者,计算共病多重用药评分(CPPS)并分析其与术前中性粒细胞淋巴细胞比值(NLR)、血小板淋巴细胞比值(PLR)和系统性免疫炎症指数(SII)的关系。结果显示CPPS严重程度越高,炎症标志物显著升高,血红蛋白显著下降,CPPS与NLR、PLR、SII呈正相关,提示共病多重用药可能与全身炎症相关,CPPS联合炎症标志物或有助于风险分层和个体化管理。

要点

  • CPPS分布:轻度22.6%、中度54.3%、重度21.9%、病态1.2%。
  • NLR从轻度3.1±2.1升至病态5.8±3.7(P<0.001)。
  • PLR从145.0±89.5升至227.2±112.9,SII从835.7±707.6升至1710.6±944.0(均P<0.001)。

核心结论

  • 较高的CPPS与炎症标志物升高和血红蛋白下降相关,提示共病和多重用药可能直接促进全身炎症。
  • CPPS联合NLR、PLR和SII可能支持CLTI患者的风险分层和个体化管理。

研究设计与样本

  • 回顾性研究,纳入442例在锡耶纳大学血管外科接受择期血运重建的CLTI患者。
  • CPPS通过慢性疾病数和长期用药数之和计算,将患者分为轻度、中度、重度、病态4组。
  • 分析术前血液检查计算NLR、PLR和SII,统计方法包括ANOVA和线性回归。

主要发现

  • CPPS分布:轻度22.6%、中度54.3%、重度21.9%、病态1.2%。
  • 平均NLR从轻度3.1±2.1升至病态5.8±3.7(P<0.001)。
  • PLR从145.0±89.5升至227.2±112.9(P<0.001),SII从835.7±707.6升至1710.6±944.0(P<0.001)。
  • 血红蛋白从13.6±2.1 g/dL降至11.5±1.7 g/dL(P=0.03)。
  • 线性回归显示CPPS与NLR(R2=0.28)、PLR(R2=0.35)、SII(R2=0.33)呈显著正相关。

临床怎么用

  • CPPS联合NLR、PLR和SII可能支持CLTI患者的风险分层和个体化管理。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic limb-threatening ischemia (CLTI) is a severe manifestation of peripheral artery disease, frequently associated with multimorbidity and polypharmacy. Chronic low-grade inflammation plays a pivotal role in atherosclerosis progression, and hematologic markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) are gaining value as prognostic tools. AIM: To investigate the relationship between the Comorbidity-Polypharmacy Score (CPPS) and inflammatory biomarkers in patients undergoing elective revascularization for CLTI. METHODS: This retrospective study included 442 CLTI patients treated at the Vascular Surgery Unit, University of Siena. CPPS was calculated by summing the number of chronic diseases and long-term medications, stratifying patients into 4 groups: mild, moderate, severe, and morbid. Pre-operative bloodwork was analyzed to calculate NLR, PLR, and SII. Statistical analysis included ANOVA and linear regression. RESULTS: CPPS distribution was mild (22.6%), moderate (54.3%), severe (21.9%), and morbid (1.2%). Inflammatory markers increased significantly with CPPS severity. Mean NLR rose from 3.1 ± 2.1 in mild to 5.8 ± 3.7 in morbid (P < 0.001), PLR from 145.0 ± 89.5 to 227.2 ± 112.9 (P < 0.001), and SII from 835.7 ± 707.6 to 1710.6 ± 944.0 (P < 0.001). Hemoglobin decreased from 13.6 ± 2.1 g/dL to 11.5 ± 1.7 g/dL (P = 0.03). Linear regression showed significant positive correlations between CPPS and NLR (R2 = 0.28), PLR (R2 = 0.35), and SII (R2 = 0.33). CONCLUSIONS: Higher CPPS is associated with elevated inflammatory markers and declining hemoglobin, suggesting that multimorbidity and polypharmacy contribute directly to systemic inflammation. CPPS, alongside NLR, PLR, and SII, may support risk stratification and personalized management in CLTI patients.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Pasqui E, Casilli G, Anichini T, et al. Linking Comorbidity and Inflammation: The Role of Comorbidity Polypharmacy Score in Chronic Limb-Threatening Ischemia. Ann Vasc Surg. 2025. PMID: 40553841. doi:10.1016/j.avsg.2025.05.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。